Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 372 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Acute Lung Injury Clear all

Conditions: Critical Illness, Sleep, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions: Dexmedetomidine, Midazolam and Fentanyl; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: ARDS, Human, Lung, Wet, Thyroid, Pulmonary Edema, Lung Inflammation
Interventions: Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation., Non-intervention; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Edina, Minnesota • Minneapolis, Minnesota

Conditions: Sepsis, Delirium, Impaired Cognition
Interventions: Dexmedetomidine, Propofol; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 11
States / cities: San Francisco, California • Baton Rouge, Louisiana • Boston, Massachusetts + 7 more

Conditions: Acute Respiratory Distress Syndrome
Interventions: CUROSURF® (poractant alfa); Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Covid-19, ARDS, Human, Acute Lung Injury
Interventions: Heparin, 0.9% Sodium-chloride; Drug
Lead sponsor: Frederick Health; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Acute Respiratory Distress Syndrome, Diaphragm Injury, Neuromuscular Blockade
Interventions: Not listed
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Boston, Massachusetts • Springfield, Massachusetts • Cleveland, Ohio + 3 more

Conditions: Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injury, Acute, Spinal Cord Injury, Spinal Cord Injury, Chronic
Interventions: OPC1; Biological
Lead sponsor: Lineage Cell Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 2
States / cities: Downey, California • La Jolla, California

Conditions: Acute Respiratory Distress Syndrome
Interventions: Not listed
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 0 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: CoronaVirus Induced Disease-2019 (COVID-19)
Interventions: Ibrutinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Stanford, California • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more

Conditions: Acute Respiratory Distress Syndrome in Children
Interventions: Either supine or prone positioning and either CMV or HFOV; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 2 Weeks to 20 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 24 more

Conditions: Covid19
Interventions: Aviptadil, Aviptadil Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Conditions: COPD, Congestive Heart Failure, Asthma, Respiratory Distress Syndrome, Adult, Pneumonia
Interventions: Not listed
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute, Myocarditis Due to Drug, Myocarditis Viral, Pericardial Diseases, Valvular Heart Diseases, Hypertension, Sepsis, Acute Kidney Injury, Pulmonary Edema - Acute, Pulmonary Edema With Heart Failure, Pulmonary Edemas, Acute Respiratory Distress Syndrome, Pulmonary Embolism Acute, Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute Massive, Pulmonary Embolism Subacute Massive, Venous Thrombosis Pulmonary, Venous Thrombosis (Disorder), Venous Thrombosis, Deep, Peripheral Arterial Disease, Peripheral Arterial Disease (PAD), Aortic Diseases, Muskuloskeletal Diseases, Brain Aging, Brain Aneurysm, Brain Aging Related Conditions, Ultrasound, Ultrasound Exams, Ultrasound Guidance
Interventions: OMNIPHYS Multimodal Ultrasound Imaging System; Device
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2046
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Respiratory Distress Syndrome, Ventilation Perfusion Mismatch
Interventions: Nitric Oxide; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ventilator-Induced Lung Injury, Sepsis Syndrome, Mechanical Ventilation Complication
Interventions: PEEP (positive end-expiratory pressure) - maximum, PEEP (positive end-expiratory pressure) - standard; Procedure
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Acute Lung Injury, Sepsis
Interventions: Ascorbic Acid, Placebo: 5% Dextrose in water; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: Atlanta, Georgia • Lexington, Kentucky • Cleveland, Ohio + 2 more

Conditions: Acute Respiratory Distress Syndrome, Ventilator Associated Pneumonia
Interventions: Non-Bronchoscopic Mini Bronchoalveolar Lavage; Other
Lead sponsor: William Janssen, MD; Other
Eligibility: 18 Years to 99 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions: IV Ganciclovir, Placebo; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 14
States / cities: Denver, Colorado • Chicago, Illinois • Springfield, Massachusetts + 10 more

Conditions: Lung Injury, Acute, Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans
Interventions: Etanercept; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 6 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: COVID, Corona Virus Infection, Respiratory Failure, Respiratory Distress Syndrome, Adult, ARDS, Human, SARS (Severe Acute Respiratory Syndrome)
Interventions: gammaCore® Sapphire (non-invasive vagus nerve stimulator), Standard of care therapies; Device · Other
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Nonintubated Acute Respiratory Distress Syndrome (ARDS), Pathogen-associated Lung Injury
Interventions: Vadadustat 900mg, Vadadustat 1200mg, Placebo; Drug
Lead sponsor: Paul Potnuru; Other
Eligibility: 18 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Respiratory Distress Syndrome, Lung Diseases, Pneumonia, Respiratory Tract Infections, Respiratory Tract Disease
Interventions: Siltuximab, Normal Saline; Drug · Other
Lead sponsor: RECORDATI GROUP; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Lansing, Michigan • Charlotte, North Carolina

Conditions: Respiratory Distress Syndrome, Adult, Lung Diseases
Interventions: Low Tidal Volume Ventilation, Positive End-Expiratory Pressure, Lysofylline, Methylprednisolone, Ketoconazole, Fluid Management, Pulmonary Artery Catheter; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2004
U.S. locations: 20
States / cities: San Francisco, California • Denver, Colorado • Chicago, Illinois + 17 more

Search by objective public record fields.

Sleep Intervention During Acute Lung Injury

Treatment of ARDS With Instilled T3

The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

Re-Evaluation of Systemic Early Neuromuscular Blockade and Transthoracic Ultrasound Assessment of the Diaphragm

A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury

Short Term Outcomes of Children With Acute Respiratory Distress Syndrome

Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

PROSpect: Prone and Oscillation Pediatric Clinical Trial

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Enhancing Utilization of Non-Invasive Positive Pressure Ventilation in Critical Care

Viral-Related Neutrophil Response and Condition Severity in People With ARDS

Multimodal Physiologic State Intelligence Study

Vascular ARDS Recruitment After Inhaled Nitric Oxide

CT for Personalized Mechanical Ventilation

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury

Macrophage Programing in Acute Lung Injury: MiniBAL

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms

Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury

SILtuximab in Viral ARds (SILVAR) Study

Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)